New research indicates that individuals who come off blockbuster GLP-1 drugs like Mounjaro or Wegovy tend to recover reduced body mass far faster than those who halt traditional lifestyle regimens.
Findings released in a leading health publication demonstrates that while overweight individuals often shed substantial amounts of their body weight while undergoing treatment, the weight is regained at an estimated rate of 0.8 kg per month upon discontinuation.
"Users buying such drugs need to be aware of the danger of rapid rebound weight gain when the treatment concludes," stated expert Dr. Susan Jebb.
That rate of regain implies a return to starting mass within about one and a half years.
Analyzing Therapies
The study, which looked at 37 of studies involving over 9,000 of participants, contrasted the effects of GLP-1 agonists with conventional dieting.
Scientists emphasize that individuals who lose weight through lifestyle changes alone generally have a less rapid creep back—around 0.1 kg a month—post-intervention.
Understanding the Rapid Regain
Nutrition scientists propose the mode of action of the drugs explains the accelerated rebound.
The injections mimic a natural hormone called glucagon-like peptide-1, which moderates feelings of fullness.
"Artificially providing GLP-1 concentrations several times higher than the body's typical production could lead to the system to generate a reduced amount of its endogenous GLP-1, and may also reduce sensitivity to its effects," said Dr. Adam Collins, a nutrition specialist.
"Stopping of this GLP-1 'fix' leads to appetite is uncontrolled, making overeating far more likely."
A Chronic Condition?
Medical guidelines suggest the jabs for people with obesity-related medical conditions, accompanied by recommended diet and exercise modifications.
Many experts say that, considering the high risk of relapse, the treatment should be considered long-term.
This opinion is supported by pharmaceutical companies, who say that the results "underscore the long-term character of obesity," comparing it to managing diseases like hypertension.
User Accounts
Users who have discontinued the medication describe a powerful return of appetite.
"It was like a trigger flipping and I was suddenly starving," recalled one woman.
This difficulty is compounded if individuals have not developed permanent lifestyle or habit modifications during treatment.
Widespread Adoption
Recent estimates indicate that millions of people in the UK have tried these injections in the past year, with demand being substantial.
- Use is more common among women than males.
- The 40s and 50s age group shows the highest level of interest.
- Many access the drugs through private healthcare rather than the NHS.
In conclusion, clinicians emphasize that while these medications are effective agents for weight loss, they are not a standalone fix and long-term success hinges on integrated lifestyle changes.
